Developer docs
API playgroundTry for free, no card

Search company profiles

SUN bioscience

Full company profile

uuid000391p

Namestring
SUN bioscience
Company typeenum
Private
Founded yearint
2016
Descriptiontext

SUN bioscience was a Swiss life-sciences tools company, founded in 2015 and based in Lausanne, that developed the Gri3D® platform — a proprietary 3D cell-based model technology for drug discovery and safety testing. The platform provided scalable organoid and spheroid culture systems designed to offer more physiologically relevant in vitro models than traditional 2D cell cultures, supporting applications in drug discovery, safety pharmacology, and toxicology testing for pharmaceutical R&D. The company's technology was positioned as reducing reliance on animal testing and improving the predictive value of preclinical outcomes.

The company was co-founded by Sylke Hoehnel (CEO) and Nathalie Brandenberg (COO), with Jeroen Van den Oever serving as CFO. Across its operating history, Sun Bioscience raised approximately $755,000 in disclosed funding from a mix of non-dilutive sources (Foundation for Innovation and Technology/FIT, MassChallenge, FOUNDER.org) and small venture rounds (Acequia Capital, Possible Ventures). The company operated with a lean team of 1–10 employees, suggesting a research-tools and platform-licensing orientation rather than a high-touch services model.

In November 2025, InSphero acquired Sun Bioscience's Gri3D® technology platform in a strategic deal to expand its 3D cell-based model portfolio, combining organoid and spheroid capabilities. Following the acquisition, the sunbioscience.ch domain was listed for auction, indicating the original legal entity was wound down and independent operations ceased. The Gri3D® technology continues under InSphero's ownership rather than as a standalone Sun Bioscience product.

Short descriptiontext

SUN bioscience was a Lausanne-based life-sciences tools company that developed the proprietary Gri3D® 3D cell-based model platform for drug discovery and safety testing by pharmaceutical companies, until its November 2025 acquisition by InSphero.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
3D cell culture, organoid technology, in vitro testing, drug discovery platforms, spheroid models
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
In Vitro Drug Discovery Platforms
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Gri3D®
Description

A platform for 3D cell culture and organoid/spheroid models used in drug discovery and safety testing.

startupticker.ch
Core offering1 text field

SUN bioscience develops the Gri3D® platform, a 3D cell-based model technology for drug discovery and safety testing. The platform provides scalable spheroid and organoid technologies that enable more physiologically relevant in vitro models compared to traditional 2D cell cultures, supporting pharmaceutical R&D decision-making in safety pharmacology and toxicology testing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SUN bioscience offers the Gri3D® platform as its core product technology for 3D cell-based models used in pharmaceutical R&D. The platform enables scalable spheroid and organoid technologies for drug discovery and safety testing applications. Based on the available information, the company's portfolio centers on this 3D cell culture technology, which was acquired by InSphero in November 2025.

Product and service1 record
1Gri3D® Platform
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

InSphero acquired Sun Bioscience's Gri3D® technology platform as part of a strategic acquisition to expand its portfolio of 3D cell-based models. The acquisition combines Sun Bioscience's organoid technology with InSphero's existing spheroid technologies, strengthening InSphero's position in the in vitro model market for drug discovery and safety testing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Swiss 3D cell-based model company specializing in spheroid and organoid technologies for drug discovery and safety testing. InSphero is the direct peer and acquirer of Sun Bioscience's Gri3D® platform, with overlapping product offerings and customer base.

TypeDirect peer
Description

Dutch organoid and organ-on-chip company developing 3D tissue models for drug discovery and toxicology. Comparable to Sun Bioscience in offering physiologically relevant in vitro models for pharma R&D customers.

3CN Bio
TypeDirect peer
Description

UK-based organ-on-chip and microphysiological systems company serving pharma drug discovery and safety testing. Directly comparable technology category (in vitro models for pharma) and customer overlap.

TypeDirect peer
Description

US organ-on-chip platform company whose Organ-Chip technology targets drug discovery and safety pharmacology use cases. Overlaps with Sun Bioscience on in vitro disease modeling for pharma customers.

TypeDirect peer
Description

German multi-organ-chip and 3D cell culture company developing microphysiological systems for pharmaceutical testing. Comparable technology stack and pharma-customer orientation to Sun Bioscience.

TypeEmerging player
Description

US 3D bioprinting and tissue engineering company focused on in vitro tissue models for drug discovery and disease modeling. Adjacent in producing 3D tissue constructs for pharma R&D but focused on bioprinting rather than organoid platforms.

TypeEmerging player
Description

US-based organ-on-chip and human-on-a-chip company providing multi-organ microphysiological systems for drug testing. Comparable in delivering physiologically relevant in vitro models for preclinical pharma applications.

TypeEmerging player
Description

Dutch live-cell imaging and cell culture monitoring company with partial overlap in 3D cell culture workflows used in drug discovery. Comparable end-market (life science research) with more limited overlap in organoid-specific technology.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SUN bioscience

In Vitro Drug Discovery Platformssunbioscience.ch

SUN bioscience was a Lausanne-based life-sciences tools company that developed the proprietary Gri3D® 3D cell-based model platform for drug discovery and safety testing by pharmaceutical companies, until its November 2025 acquisition by InSphero.

What SUN bioscience does

SUN bioscience was a Swiss life-sciences tools company, founded in 2015 and based in Lausanne, that developed the Gri3D® platform — a proprietary 3D cell-based model technology for drug discovery and safety testing. The platform provided scalable organoid and spheroid culture systems designed to offer more physiologically relevant in vitro models than traditional 2D cell cultures, supporting applications in drug discovery, safety pharmacology, and toxicology testing for pharmaceutical R&D. The company's technology was positioned as reducing reliance on animal testing and improving the predictive value of preclinical outcomes.

The company was co-founded by Sylke Hoehnel (CEO) and Nathalie Brandenberg (COO), with Jeroen Van den Oever serving as CFO. Across its operating history, Sun Bioscience raised approximately $755,000 in disclosed funding from a mix of non-dilutive sources (Foundation for Innovation and Technology/FIT, MassChallenge, FOUNDER.org) and small venture rounds (Acequia Capital, Possible Ventures). The company operated with a lean team of 1–10 employees, suggesting a research-tools and platform-licensing orientation rather than a high-touch services model.

In November 2025, InSphero acquired Sun Bioscience's Gri3D® technology platform in a strategic deal to expand its 3D cell-based model portfolio, combining organoid and spheroid capabilities. Following the acquisition, the sunbioscience.ch domain was listed for auction, indicating the original legal entity was wound down and independent operations ceased. The Gri3D® technology continues under InSphero's ownership rather than as a standalone Sun Bioscience product.

SUN bioscience firmographics

Firmographics
Name
SUN bioscience
Website
https://sunbioscience.ch
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
1–10 employees
Short description
SUN bioscience was a Lausanne-based life-sciences tools company that developed the proprietary Gri3D® 3D cell-based model platform for drug discovery and safety testing by pharmaceutical companies, until its November 2025 acquisition by InSphero.
Ownership category
akta.pro rank

SUN bioscience industry classification

Industry
Product category
In Vitro Drug Discovery Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • 3D cell culture
  • Organoid technology
  • In vitro testing
  • Drug discovery platforms
  • Spheroid models

Where SUN bioscience is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Markets served

SUN bioscience business model

Business model
GTM type
B2B
Offering type
Services

SUN bioscience product offering

Product offering

Core offering

SUN bioscience develops the Gri3D® platform, a 3D cell-based model technology for drug discovery and safety testing. The platform provides scalable spheroid and organoid technologies that enable more physiologically relevant in vitro models compared to traditional 2D cell cultures, supporting pharmaceutical R&D decision-making in safety pharmacology and toxicology testing.

Product overview

SUN bioscience offers the Gri3D® platform as its core product technology for 3D cell-based models used in pharmaceutical R&D. The platform enables scalable spheroid and organoid technologies for drug discovery and safety testing applications. Based on the available information, the company's portfolio centers on this 3D cell culture technology, which was acquired by InSphero in November 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Gri3D®: A platform for 3D cell culture and organoid/spheroid models used in drug discovery and safety testing.

Products and services

  • Gri3D® Platform

Companies that use SUN bioscience

Customer profile

Segments1 record

SUN bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SUN bioscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • InSpherocoreStrategic or Co-development Partner · 11 November 2025InSphero acquired Sun Bioscience's Gri3D® technology platform as part of a strategic acquisition to expand its portfolio of 3D cell-based models. The acquisition combines Sun Bioscience's organoid technology with InSphero's existing spheroid technologies, strengthening InSphero's position in the in vitro model market for drug discovery and safety testing.

Recent moves6 records

Expansion highlights2 records

SUN bioscience competitors and assessment

Company assessment

Direct peers

  • InSphero: Swiss 3D cell-based model company specializing in spheroid and organoid technologies for drug discovery and safety testing. InSphero is the direct peer and acquirer of Sun Bioscience's Gri3D® platform, with overlapping product offerings and customer base.
  • Mimetas: Dutch organoid and organ-on-chip company developing 3D tissue models for drug discovery and toxicology. Comparable to Sun Bioscience in offering physiologically relevant in vitro models for pharma R&D customers.
  • CN Bio: UK-based organ-on-chip and microphysiological systems company serving pharma drug discovery and safety testing. Directly comparable technology category (in vitro models for pharma) and customer overlap.
  • Emulate: US organ-on-chip platform company whose Organ-Chip technology targets drug discovery and safety pharmacology use cases. Overlaps with Sun Bioscience on in vitro disease modeling for pharma customers.
  • TissUse: German multi-organ-chip and 3D cell culture company developing microphysiological systems for pharmaceutical testing. Comparable technology stack and pharma-customer orientation to Sun Bioscience.

Emerging players

  • Organovo: US 3D bioprinting and tissue engineering company focused on in vitro tissue models for drug discovery and disease modeling. Adjacent in producing 3D tissue constructs for pharma R&D but focused on bioprinting rather than organoid platforms.
  • Hesperos: US-based organ-on-chip and human-on-a-chip company providing multi-organ microphysiological systems for drug testing. Comparable in delivering physiologically relevant in vitro models for preclinical pharma applications.
  • CytoSMART: Dutch live-cell imaging and cell culture monitoring company with partial overlap in 3D cell culture workflows used in drug discovery. Comparable end-market (life science research) with more limited overlap in organoid-specific technology.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

SUN bioscience social profiles

Digital presence

SUN bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SUN bioscience leadership team

Management profile

Number of profiles

SUN bioscience funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SUN bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SUN bioscience

What does SUN bioscience do?

SUN bioscience develops the Gri3D® platform, a 3D cell-based model technology for drug discovery and safety testing. The platform provides scalable spheroid and organoid technologies that enable more physiologically relevant in vitro models compared to traditional 2D cell cultures, supporting pharmaceutical R&D decision-making in safety pharmacology and toxicology testing.

Is SUN bioscience a public or private company?

SUN bioscience is a private company. It is classified as corporate owned and is currently acquired.

When was SUN bioscience founded?

SUN bioscience was founded in 2016. It employs 1 to 10 people.

Where is SUN bioscience based?

SUN bioscience is headquartered in Lausanne, Switzerland, in the Europe region.

Who are SUN bioscience's main competitors?

Direct peers on record are InSphero, Mimetas, CN Bio, Emulate and TissUse. Emerging players are Organovo, Hesperos and CytoSMART.

Does SUN bioscience have an API?

No public API is recorded for SUN bioscience.

What industry is SUN bioscience in?

SUN bioscience's product category is In Vitro Drug Discovery Platforms. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioAlpsInSphero acquires DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a global market leader in 3D cell-based assays and organ-on-chip systems, signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technology including Sun Bioscience's Gri3D® platform. The acquisition combines scalable spheroid and organoid technologies, enabling InSphero to offer a unified 3D model ecosystem from standardized spheroids to complex organoids for pharmaceutical research and drug discovery. This strategic move positions InSphero to better serve pharmaceutical, biotechnology, and academic customers seeking human-relevant 3D in vitro models to replace animal testing.EIN PresswireInSphero Expands 3D Cell Model Leadership with Acquisition of DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a Swiss 3D cell-based assay company, signed a definitive agreement to acquire DOPPL SA, a Lausanne-based organoid innovator, along with the Sun Bioscience Gri3D® technology platform. The acquisition combines scalable spheroid technologies with Sun Bioscience's organoid culture platform and DOPPL's assay development expertise to create a unified 3D model ecosystem for pharmaceutical R&D and drug discovery. The move positions InSphero as a comprehensive provider offering the full spectrum of 3D in vitro models, from standardized spheroids to complex patient-derived organoids, under one roof.startupticker.chInSphero acquires DOPPL SA and Sun Bioscience Gri3D TechnologyInSphero AG, a global market leader in 3D cell-based assays and organ-on-chip systems, has signed a definitive agreement to acquire DOPPL SA and Sun Bioscience's Gri3D technology. The acquisition combines InSphero's scalable spheroid technology with Sun Bioscience's Gri3D organoid culture platform and DOPPL's expertise in organoid assay development, creating what the company calls the most comprehensive 3D in vitro model offering. The deal aims to provide pharmaceutical, biotech, and academic customers with a unified ecosystem spanning from standardized spheroids to patient-derived organoid models for drug discovery and safety testing.startupticker.chSUN Bioscience Organoid Production gets FIT boostSUN Bioscience has secured a CHF 500,000 Tech Growth loan from the Foundation for Technological Innovation (FIT) to scale its industrial organoid production technology. The funding will enable the startup to hire additional staff and expand its commercial facilities, including plans for US expansion by 2022. This capital supports the company's goal of providing automated, high-throughput 3D cell culture systems for pharmaceutical research.startupticker.chSUN Bioscience wins 27th Prix StrategisSUN Bioscience won the 27th Prix Strategis, receiving CHF 50,000 for its tissue culture technology. The startup, founded in 2016 by EPFL researchers, aims to offer a low-cost solution for organoid culture to the pharmaceutical industry. The ceremony was held in Lausanne with Patrick Aebischer as guest speaker.startupticker.chSUN Bioscience selected for StartLab IncubatorSUN Bioscience, a Swiss bioengineering startup, joined Biopôle's StartLab incubator in Epalinges as the fifth company. Its Gri3D platform for 3D organoid cultures is being used for a cystic fibrosis diagnostic test, with a clinical pilot involving 15 patients. The company plans to expand its customer portfolio and move toward human organoid cultures.startupticker.chUnbreakable cables, wearable muscles and saving billions in healthcare costsFive startups won CHF 100,000 each at the W.A. de Vigier award ceremony, with Sylke Hoehnel winning the audience award. The winners include AUDATIC, inVoli, MyoSwiss, nanoleq, and SUN bioscience, offering solutions for hearing aids, drone integration, wearable muscles, cables, and 3D cell cultures. The foundation selected from over 220 submitted projects.